UPDATE: CIGNA Raises PT

According to a research report published earlier today, Wedbush has increased CIGNA's CI PT from $52 to $53. In the report, CIGNA commented, “We are increasing our price target to $53 from $52 as investor concern turns to positive sentiment with court hearings over. We are decreasing our 2012E to $5.57 as March Medicare Advantage enrollment data from CMS was 40K, or 10%, and Part D 186K, or 15% below our estimate, which lowers our full-year estimates by $0.04 and $0.02, respectively. We also modestly increase SG&A estimates related to HealthSpring integration and modest deleveraging from changes in membership.” Wedbush maintains its Neutral rating on CIGNA, which is currently trading at $47.77.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsWedbush
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!